UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 257

Sortiert nach

Clinical utility of gene-expression signatures in early stage breast cancer

Nature reviews. Clinical oncology, 2017-10, Vol.14 (10), p.595-610

2017

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy and targeted therapy combinations in metastatic breast cancer

The lancet oncology, 2019-03, Vol.20 (3), p.e175-e186

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3

Journal of clinical oncology, 2018-08, Vol.36 (24), p.2465-2472

2018

Link zum Volltext

Verfügbarkeit prüfen

HER2 therapy: molecular mechanisms of trastuzumab resistance

Breast cancer research : BCR, 2006-01, Vol.8 (6), p.215-215, Article 215

2006

Link zum Volltext

Verfügbarkeit prüfen

Herceptin: mechanisms of action and resistance

Cancer letters, 2006-02, Vol.232 (2), p.123-138

2006

Link zum Volltext

Verfügbarkeit prüfen

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2615-2623

2012

Link zum Volltext

Verfügbarkeit prüfen

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Nature medicine, 2011-04, Vol.17 (4), p.461-469

2011

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes

Oncotarget, 2014-10, Vol.5 (20), p.9864-9876

2014

Link zum Volltext

Verfügbarkeit prüfen

Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

Cancers, 2024-02, Vol.16 (4), p.800

2024

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Nature clinical practice. Oncology, 2006-05, Vol.3 (5), p.269-280

2006

Link zum Volltext

Verfügbarkeit prüfen

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Cancer research (Chicago, Ill.), 2005-12, Vol.65 (23), p.11118-11128

2005

Link zum Volltext

Verfügbarkeit prüfen

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry

Journal of clinical oncology, 2012-03, Vol.30 (7), p.729-734

2012

Link zum Volltext

Verfügbarkeit prüfen

Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer

Journal of mammary gland biology and neoplasia, 2008-12, Vol.13 (4), p.485-498

2008

Link zum Volltext

Verfügbarkeit prüfen

Antibody-drug conjugates in triple negative breast cancer

Future oncology (London, England), 2018-10, Vol.14 (25), p.2651-2661

2018

Link zum Volltext

Verfügbarkeit prüfen

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells

Cancer research (Chicago, Ill.), 2004-04, Vol.64 (7), p.2343-2346

2004

Link zum Volltext

Verfügbarkeit prüfen

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Cancer cell, 2004-08, Vol.6 (2), p.117-127

2004

Link zum Volltext

Verfügbarkeit prüfen

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

Clinical cancer research, 2009-12, Vol.15 (23), p.7381-7388

2009

Link zum Volltext

Verfügbarkeit prüfen

Early breast cancer

The Lancet (British edition), 2009-04, Vol.373 (9673), p.1463-1479

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

Journal of clinical oncology, 2011-08, Vol.29 (23), p.3126-3132

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

Breast cancer research : BCR, 2017-08, Vol.19 (1), p.89-8, Article 89

2017

Link zum Volltext

Verfügbarkeit prüfen

A new paradigm for classifying and treating HER2‐positive breast cancer

Cancer reports, 2023-08, Vol.6 (8), p.e1841-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.667-674

2007

Link zum Volltext

Verfügbarkeit prüfen

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Breast (Edinburgh), 2020-12, Vol.54, p.148-154

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 257

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(245)
Mit Volltextzugriff
(241)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical utility of gene-expression signatures in early stage breast cancer

Immunotherapy and targeted therapy combinations in metastatic breast cancer

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3

HER2 therapy: molecular mechanisms of trastuzumab resistance

Herceptin: mechanisms of action and resistance

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes

Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry

Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

Antibody-drug conjugates in triple negative breast cancer

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

Early breast cancer

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

A new paradigm for classifying and treating HER2‐positive breast cancer

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Suchergebnisse filtern